This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

A Busy Week For Bio-Pharma Earnings, Drug Approvals

BOSTON ( TheStreet) -- Investors, get ready for a very busy week of biotech and pharmaceutical earnings and FDA drug decision approvals.

Monday, July 23

InterMune (ITMN) will announce second-quarter financial results before the opening bell. Investors will be focused on sales of Esbriet, which InterMune is selling in Europe as a treatment for the serious lung disease idiopathic pulmonary fibrosis. The consensus sales estimate for Esbriet in the June quarter is $7.8 million.

Also watch for what InterMune says about new patient starts on Esbriet in the quarter. First quarter new-patient adds dipped to 363 in the first quarter from 402 in the fourth quarter 2011. Given the new, more favorable reimbursement opinion in Germany, new patients on Esbriet should have rebounded and started to grow again in the June quarter.

InterMune is expected to lose 28 cents a share on total revenue of $36.35 million in the second quarter.

Amylin Pharmaceuticals (AMLN) and Human Genome Sciences (HGSI) also report second-quarter results on Monday but are less important given the in-process acquisitions by Bristol-Myers Squibb (BMY) and GlaxoSmithKline (GSK), respectively.

Tuesday, July 24

Biogen Idec (BIIB - Get Report) earnings on tap, with current consensus pegged at earnings of $1.56 per share on total revenue of $1.33 billion for the June quarter.

Drilling deeper in Biogen June earnings, worldwide sales of the multiple sclerosis drug Tysabri are expected to total $415 million, with between 140 to 150 new patients starts per week in the quarter. Consensus sales estimate for Avonex, the company's other multiple sclerosis drug, is $428 million in the U.S. and $269 million ex-U.S.

Questcor Pharmaceuticals (QCOR) reports second-quarter earnings, with analysts on average expected 63 cents per share on total revenue of $108.9 million.

Wednesday, July 25

When Alexion Pharmaceuticals (ALXN) reports June quarter results, look for earnings of 37 cents per share on total revenue (Soliris sales) of $263 million.

Regeneron Pharmaceuticals (REGN) second-quarter earnings: Consensus 25 cents per share on $255.9 million.

Also reporting Wednesday are Bristol-Myers Squibb, Eli Lilly (LLY) and GlaxoSmithKline.

Thursday July 26

The biggest day of the week, headlined by two FDA drug approval decisions: marin's (AMRN - Get Report) prescription fish-oil pill Vascepa and Horizon Pharmaceutical's (HZNP - Get Report) Lodotra, a long-acting formulation of the common steroid prednisone intended for rheumatoid arthritis pain relief.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
AMRN $2.41 0.00%
BIIB $429.87 0.00%
CELG $118.68 0.00%
GILD $101.00 0.00%
HZNP $21.81 0.00%


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs